HCA Healthcare (HCA)
(Delayed Data from NYSE)
$306.69 USD
-7.43 (-2.37%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $306.50 -0.19 (-0.06%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$306.69 USD
-7.43 (-2.37%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $306.50 -0.19 (-0.06%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth B Momentum A VGM
Zacks News
HCA Healthcare's (HCA) Q1 Earnings Beat on Rising Admissions
by Zacks Equity Research
HCA Healthcare's (HCA) quarterly results gain from broad volume-based growth along with a rising number of surgeries. Rising expenses act as a partial offset.
HCA (HCA) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for HCA (HCA) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
HCA Healthcare (HCA) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
HCA (HCA) delivered earnings and revenue surprises of 6.99% and 2.93%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ResMed (RMD) Q3 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
ResMed's (RMD) fiscal 2024 third-quarter performance reflects another strong period of execution across the entire business, resulting in impressive top and bottom-line growth.
The Zacks Analyst Blog Highlights Cigna Group, HCA Healthcare, Avantor and Tenet Healthcare
by Zacks Equity Research
Cigna Group, HCA Healthcare, Avantor and Tenet Healthcare are part of the Zacks top Analyst Blog.
Stay Ahead With 4 Healthcare Stocks Poised for Q1 Earnings Beat
by Kaibalya Pravo Dey
Growing patient volumes, advancements in technology, admissions, premium rate hikes and other factors are likely to have benefited healthcare players during Q1. Companies like CI, HCA, AVTR and THC can outperform.
Why Earnings Season Could Be Great for HCA Healthcare (HCA)
by Zacks Equity Research
HCA Healthcare (HCA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zacks.com featured highlights include Hubbel, Caterpillar, The Timken Co. and HCA Healthcare
by Zacks Equity Research
Hubbel, Caterpillar, The Timken Co. and HCA Healthcare are part of the Zacks Screen of the Week article.
Community Health Systems (CYH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Community Health Systems (CYH) delivered earnings and revenue surprises of 26.32% and 1.49%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Scoop up These 4 GARP Stocks to Receive Handsome Returns
by Zacks Equity Research
The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. HUBB, CAT, TKR and HCA are some stocks that hold promise.
Why HCA Healthcare (HCA) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Earnings Growth & Price Strength Make HCA Healthcare (HCA) a Stock to Watch
by Zacks Equity Research
The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Insulet (PODD) Awaits Q1 Earnings Release: Here's What to Expect
by Zacks Equity Research
Strong global new customer starts fueled by the ongoing Omnipod 5 demand are expected to significantly benefit Insulet's (PODD) first-quarter performance.
Can Higher Visits Soften Cost Blow for Teladoc (TDOC) in Q1?
by Zacks Equity Research
Teladoc's (TDOC) first-quarter results are expected to have benefited from higher visits. However, high costs might have partially offset the positives.
Tenet Healthcare (THC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Tenet (THC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is It Worth Investing in HCA (HCA) Based on Wall Street's Bullish Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in HCA (HCA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Ahead of HCA (HCA) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of HCA (HCA) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Should You Buy HCA Healthcare (HCA) Ahead of Q1 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) first-quarter results are likely to reflect increased admissions and patient days.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Why HCA Healthcare (HCA) Outpaced the Stock Market Today
by Zacks Equity Research
In the closing of the recent trading day, HCA Healthcare (HCA) stood at $310.31, denoting a +1.7% change from the preceding trading day.
Should You Buy Encompass Health (EHC) Ahead of Q1 Earnings?
by Zacks Equity Research
Encompass Health's (EHC) Q1 results are likely to benefit on the back of growing patient volumes and commendable expansion initiatives.
Will Acute Care Unit Aid Universal Health's (UHS) Q1 Earnings?
by Zacks Equity Research
Universal Health's (UHS) Q1 results are expected to be aided by growing patient volumes and surgical cases, partly offset by increased expenses.
HCA Healthcare (HCA) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
HCA (HCA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Large-Cap Medical Stocks to Buy Ahead of Q1 Earnings
by Nalak Das
We have narrowed our search to five S&P 500 medical stocks that are poised to beat on first-quarter earnings results.These are: HCA, UHS, LH, EW, PODD.
Here's Why HCA Healthcare (HCA) Fell More Than Broader Market
by Zacks Equity Research
In the latest trading session, HCA Healthcare (HCA) closed at $311.03, marking a -0.91% move from the previous day.